Tortugas’ Obuprazine Beats Placebo in Phase 2b Schizophrenia Study
Tortugas reports obuprazine beat placebo at all doses in a 363-patient Phase 2b. Five claims checked against the evidence, plus what is still missing.
Read More
Supreme Court Pushes Beyond Cancer Drugs on Medicine Prices
Judges asked why India’s 30% cancer drug margin cap should not cover other medicines. What changes for makers, chemists, hospitals and patients.
Stryker Invests $400M in CMR Surgical: What the Deal Covers
Stryker commits about $400M to CMR Surgical, gains US Versius sales rights and a buy-out option. Answers on terms, risks and what is still undisclosed.
FDA Early Alert: Philips Lumify Ultrasound Issue, Four Deaths Reported
Philips Lumify ultrasound FDA safety alert: four deaths and eight serious injuries reported over two faults. What the FDA said and what users should do.
Experimental Eye Treatment CSB-001 Shows Promising Vision Gains in Clinical Study
CSB-001 eye treatment gave 41% of treated eyes 15+ letters in an open-label limbal stem cell deficiency study. The data, the limits and what comes next.
Sahajanand Medical Technologies IPO: ₹327–₹344 Price Band Announced for ₹475 Crore Issue
Sahajanand Medical Technologies IPO opens 15 October at ₹327-344, a ₹475 crore offer for sale. Dates, lot size, financials, valuation and risks.
FDA Grants Fast Track Status to New Biliary Tract Cancer Immunotherapy, Opamtistomig
Opamtistomig FDA Fast Track granted for first-line biliary tract cancer, nine days after filing. What it means, the data so far and what is unknown.
Mystery Surrounds Young Worker’s Death at Russia Lab Studying Severe Diseases
Russia lab worker death: a young employee of a plague institute died of pneumonia. WHO sees no spread, 5,500 tests found no pathogen, cause unknown.
Alumis Reports 48-Week Phase 3 Data for Envudeucitinib in Plaque Psoriasis
Envudeucitinib plaque psoriasis: Alumis reports 54% complete skin clearance at 48 weeks in Phase 3 ONWARD3 and plans an NDA in Q4 2026.